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Abstract Human neutrophil PLD activity stimulated with GTP-y-S was reconstituted with recombinant ARFl in cytosol-depleted cells. PMA- 
pretreatment of intact cells greatly enhanced the subsequent reconstitution of the ARFl-regulated PLD activity. This enhancement was only observed 
provided that the intact cells were pretreated with PMA, suggesting the stable recruitment of a cytosolic component, presumably protein kinase C, 
to the membranes. rARFl-reconstituted PLD activity was not dependent on MgATP, but could be considerably enhanced by MgATP. Maximal 
effects of MgATP were seen at 1 mM. This enhancement by MgATP could not be attributed to protein kinase C. Neomycin was found to inhibit 
ARFl-regulated PLD activity suggesting the requirement for polyphosphoinositides. We conclude: (i) that many of the observed effects of PMA may 
be dependent on the presence of the small GTP-binding protein, ARF, and (ii) polyphosphoinositides are required for ARFl-stimulated PLD activity. 
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1. Introduction 
Phospholipase D (PLD) hydrolyses phosphatidylcholine 
(PC) to phosphatidic acid (PA) and choline. In intact cells, this 
enzyme activity is stimulated by a number of cell-surface recep- 
tors including G-protein-coupled receptors as well as receptors 
that use tyrosine kinase as their signaling mechanism [1,2]. In 
addition to receptor-directed agonists, both PMA, a protein 
kinase C (PKC) activator, and Ca” ionophores activate PLD 
activity in many cell types [l] including neutrophils [2-4]. Fur- 
ther evidence in support of PKC comes from studies where 
down regulation of PKC abolished agonist-stimulated PLD 
activity [5] whilst overexpression of PKC a or /I1 isoforms 
upregulates both PMA-activated as well as receptor-activated 
PLD activity [68]. More recently it has been reported that 
direct addition of PKC isoforms /3 or a stimulated PLD activity 
in membranes [9]. 
From studies in permeabilized cells and other cell-free sys- 
tems, it has emerged that PLD activity can be regulated by 
guanine nucleotides indicating a role for a putative GTP-bind- 
ing protein [l&12]. Several studies have indicated that maximal 
PLD activity required the interplay of PKC and a GTP-binding 
protein [11,12]. In neutrophils and the related cell-line HL60, 
many studies have indicated that there is a requirement for both 
cytosol and membranes to observe GTP-y-S-regulated PLD 
activity [13-151. In HL60 cells, the cytosolic factor has now 
been identified as two highly-related small GTP binding pro- 
teins of the ARF family, ARFl and ARF3 [16,17]. 
We show that ARFl regulates PLD in human neutrophils 
and this activity can be modulated by PMA pretreatment and 
by MgATP. When PMA is used to recruit PKC to membranes 
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prior to cytosol-depletion, ARFl-reconstituted PLD activity is 
enhanced. MgATP also increased ARFl-reconstituted PLD 
activity and this effect was attributed to the increased availabil- 
ity of polyphosphoinositides. We conclude (i) that many of the 
observed effects of PMA may be dependent on the presence of 
the small GTP-binding protein, ARF and (ii) polyphosphoinos- 
itides are required for ARFl-stimulated PLD activity. 
2. Materials and methods 
2.1. Materials 
All reagents were obtained as previously specified [12]. Recombinant 
ARFl (rARF1) was prepared as described previously [17]. 
2.2. Preparation of human neutrophils 
Human neutrophils were prepared by established procedures from 
50 ml of anti-coagulated blood obtained from healthy volunteers [18]. 
In brief, after sedimentation of red cells with an equal volume of 2% 
dextran in phosphate buffered saline (0.9%) (pH 7.2), the leucocytes 
were layered onto Ficoll-hypaque and centrifuged at 2,000 rpm for 
20 min to separate the neutrophils from other white cells. The contam- 
inating red cells were removed by hypotonic lysis. Typical yield of 
neutrophils from 50 ml of blood was 5-8 x 10’ cells. 
2.3. Labelling of neutrophils with [3H]alkyl-lyso-PC 
Neutrophils (5-8 x 10’ cells) were washed twice in HEPES buffer (20 
mM HEPES, 137 mM NaCl, 2.7 mM KCl, 5.6 mM glucose, 1 mM 
MgCl,, 1 mM CaCl, and 0.1 mg/ml BSA, pH 7.2) and finally resus- 
pended in 2 ml. The cells were incubated at 37’C with [‘Hlalkyl-lyso-PC 
(10 &i) for 30 min. Lyso-PC is incorporated into the cells and rapidly 
acylated to PC. The majority of the label is found in PC (Fig. 3A). The 
labelled cells were sedimented by centrifugation to remove unincorpo- 
rated label and the cells washed with PIPES buffer (20 mM PIPES, 137 
mM NaCl, 2.7 mM KCI, 5.6 mM glucose, and 0.1 mg/ml BSA, pH 6.8). 
2.4. Assay for GTP-y-S-dependent PLD activity in permeabilized cells 
The labelled cells were suspended in PIPES buffer and aliquots 
(25 ~1) transferred to tubes containing 0.4 i.u./ml streptolysin 0, 
MgATP (1 mM), MgCl, (2 mM), EtOH (1%). The Ca” concentration 
was maintained with Ca2’. EGTA buffers as described previously [19]. 
GTP-y-S (10 PM) was also present where indicated. These cells are 
referred to as ‘acutely permeabilized’. 
After incubation for 30 min at 37°C the samples were quenched with 
500 ~1 chloroform/methanol (1: 1, v/v). After phase separation with 
250 ~1 of water, the chloroform phase was recovered and a mixture of PA 
and PEt [12] was added for localization of the lipids with brief staining 
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with I, vapour. Radiolabelled PA, PEt and PC were separated by tic 
in a solvent system using ChCl,/MeOH/acetic acid/H,0 (75 : 45 : 3 : 1, by 
volume) on oxalate-treated plates as described previously [12]. The tic 
plates were either analysed by two methods. The spots identified as PA, 
PEt and PC were scraped and counted by liquid scintillation. In some 
experiments, the tic plate was put into contact with a phosphor imaging 
plate and the results scanned on a Fuji Bioimage analyser. 
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2.5. Reconstitution of ARF-regulated PLD in cytosol-depleted cells 
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The labelled cells were suspended in 4.5 ml of PIPES buffer and 
permeabilized with streptolysin 0 (0.4 IU/ml) for 10 min at 37°C [17]. 
The cells were then diluted with 40 ml of ice-cold PIPES buffer and 
centrifuged to remove the leaked cytosol. These cells are referred to as 
‘cytosol-depleted’ cells. PLD activation was initiated by adding 25 ~1 
of cytosol-depleted cells to tubes containing rARF1 (40 PM), GTP-y-S 
(lOpM), Ca2’ (1 PM, buffered with 3 mM EGTA), ethanol (1%) MgCl, 
(2 mM) and MgATP (1 mM) as indicated in a final volume of 100 ~1. 
Assays were processed as for the ‘acutely permeabilized’ cells. 
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2.6. Metabolic inhibition of cells prior to permeabilization 
In those experiments where intracellular ATP levels were depleted 
prior to permeabilization, glucose was omitted from the permeabiliza- 
tion buffer. The cells were metabolically inhibited by incubation with 
5.6 mM deoxyglucose and 5 PM antimycin A for 5 min at 37°C before 
the addition of streptolysin 0. 
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2.7. Presentation of results 
All determinations were performed in duplicate and did not vary by 
more than 5%. The data shown are from representative experiments. 
All experiments were repeated under identical conditions and most 
observations were verified on 34 occasions with slight modifications 
in the protocol. 
3. Results 
3.1. rARF1 reconstitutes PLD activity in cytosol-depleted 
neutrophils 
PLD catalyses the hydrolytic cleavage of the terminal 
phosphodiester bond of PC with the formation of PA and the 
water-soluble headgroup, choline. In the experiments reported 
here, the PC pool is specifically labelled by incubating human 
neutrophils with lyso-PC. This is readily taken up by cells and 
acylated to PC (see Fig. 3A). A property of PLD is the unique 
ability to transfer the phosphatidyl portion of the PC molecule 
to appropriate nucleophiles such as ethanol. In this case, the 
product that is formed is phosphatidylethanol (PEt). Due to its 
stability and also because it is an unambiguous product of PLD 
activity, production of PEt was monitored in the experiments 
described below. 
Fig. 1A illustrates that addition of GTP-y-S simultaneously 
with the permeabilizing agent, streptolysin 0 (SLO), to human 
neutrophils results in the activation of PLD. (These cells are 
referred to as acutely-permeabilized). Transphosphatidylation, 
in the presence of 1% ethanol, is always incomplete and there- 
fore PEt is always accompanied by a corresponding increase in 
PA (Fig. lB, see also Fig. 3A). Activation of PLD by GTP-y-S 
is impaired when the cells are permeabilized first to deplete the 
endogenous cytosolic proteins (Fig. lA,B). Some GTP-y-S- 
regulated PLD activity is always retained and this is due to the 
presence of membrane-associated ARF proteins (data not 
shown). Incubation of the cytosol-depleted cells with rARF1 
more than fully restores the ability of GTP-y-S to activate the 
endogenous PLD (Fig. lA,B). 
Addition of rARF1 alone has little effect on PLD activity in 
cytosol-depleted neutrophils but in the presence of GTP-y-S, 
rARF1 stimulates PLD activity in a concentration-dependent 
a b C 
Fig. 1. rARF1 can restore GTP-y-S-stimulated PLD activity in cytosol- 
denleted human neutronhils (A) PEt and (B) PA. (a) Neutronhils were 
permeabilized with streptolysin’o f 10 &I’GTP-i:S. (b) Neutrophils 
were permeabilized with streptolysin 0 for 10 min to deplete the cy- 
tosolic proteins, washed and then incubated + 10 PM GTP-y-S. 
(c) Cytosol-depleted cells as in (b) were incubated with rARF1 (4 nmoll 
assak 40 PM) f 10 PM GTP-r-S. The PLD activity was assayed for 
30 min in the presence of 1 mM MgATP, 1 PM Ca*’ and 1% ethanol 
(assay volume, 100 PI). 
manner (Fig. 2A). Near maximal activation is observed at 
5 nmol of rARF1, i.e. 50pM. rARF1 used in these experiments 
is not myristoylated and therefore it is required at 100 times 
greater concentration compared to myristoylated ARF 1 [ 171. 
To test the requirement for Ca’+, neutrophils were reconsti- 
tuted with rARF1 either in the presence of Ca” buffered at pCa 
8 (10 nM) or pCa 6 (1 PM) (Fig. 2B). In the absence of GTP- 
y-S, Ca2’ alone at either concentration does not influence PLD 
activity. GTP-y-S induced a robust activation of PLD at either 
Ca2’ concentration; the response was always slightly greater at 
1 PM compared to 10 nM. 
3.2. PMA pretreatment enhances rARFl-reconstituted PLD 
activity 
The phorbol ester, PMA has been shown to stimulate PLD 
activity in many cell-types including human neutrophils [ 1,2,4]. 
We therefore xamined the influence of PMA on rARFl-recon- 
stituted PLD activities. The intact cells were pretreated with 
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Fig. 2 rARFl-stimulated PLD activity (A) concentration dependence 
of rARFl and (B) dependence on Ca*‘. (A) Cytosol-depleted neutro- 
phils were assayed for PLD activity for 30min in the presence of 1 mM 
MgATP, 1 PM Ca”’ and 1% ethanol in the presence or absence of 
GTP-y-S (10 PM). (B) Legend as in A except that rARF1 was 4nmoV 
assay and Ca” was present at 10 nM or 1 ,uM Ca*‘. 
100 nM PMA for 5 min and then permeabilized for 10 min to 
remove the endogenous proteins. The control cells and PMA- 
pretreated cells were then reconstituted with rARF1. In the 
control cells, increases in PA and PEt are seen in the presence 
of GTP-y-S and rARF1 only (Fig. 3A). Pretreatment with 
PMA doubles the rARF1 reconstitution of GTP-y-S-stimu- 
lated PLD activity (Fig. 3A,B). It should be noted that PMA 
pretreatment alone raised both basal and GTP-y-S-stimulated 
PLD activity. These increases are probably dependent on the 
residual endogenous ARF proteins. In addition to the rise in 
PA and PEt, it was also noted that there was a substantial 
increment in radioactivity in the region where neutral lipids run 
(Fig. 3A). Preliminary data indicate that these changes are in 
mono- and diglycerides as well as an unidentified lipid. This 
increase in the neutral lipids were particularly observed in 
PMA-pretreated cells suggesting that PMA stimulated an addi- 
tional lipase activity, possibly a PC-PLC. 
Enhancement of rARFl-reconstituted PLD activity by PMA 
was only observed when the cells were treated with PMA prior 
to permeabilization (Fig. 3B). Direct addition of PMA during 
the assay had no effect. This implies that PMA allows the 
recruitment of a factor from the cytosol during the pretreat- 
ment of the intact cells. The factor must be stably-associated 
with the cell membranes, since the cells are permeabilised with 
SLO for 1Omin and subsequently washed. 
3.3. Effects of MgATP on rARFl-regulated PLD activity 
It has been previously demonstrated that MgATP will en- 
hance GTP-y-S-stimulated PLD activity in permeabilized 
HL60 cells [12, 201. This enhancement by MgATP was attri- 
buted to the activation of G-protein-mediated PLC and hence 
to the activation of PKC [ 12,191. It was therefore of interest to 
examine whether reconstitution of PLD activity in cytosol- 
depleted neutrophils with rARF1 was also affected by MgATP. 
In cytosol-depleted HL60 cells, GTP-y-S-mediated activation 
of PLC is impaired due to loss of another cytosolic protein, 
phosphatidylinositol transfer protein [21]. Fig. 4A demon- 
strates that rARFl-reconstituted PLD activity is substantial in 
the absence of MgATP. However, in the presence of MgATP, 
it more than doubles. 
The concentration of MgATP required for maximal potenti- 
ation is 1 mM, with half maximal at 100 PM. This requirement 
for MgATP excludes protein kinases since they have a half 
maximal requirement in the ,uM range [22]. Inositol lipid ki- 
nases, however, show such a MgATP dependence [19]. In order 
to investigate whether the requirement for MgATP reflects the 
involvement of polyphosphoinositides, we examined the effect 
of neomycin. Neomycin inhibited both the MgATP- dependent 
and independent components of PLD activity. The MgATP- 
dependent component was inhibited by 80% whilst the 
MgATP-independent component by 60% (Fig. 4B). 
It has been demonstrated that wortmannin specifically inhib- 
its phosphoinositide 3-kinase (PI 3-kinase) in neutrophils, thus 
preventing the fMetLeuPhe-mediated production of PIP, 
[23,24]. We have examined the effect of wortmannin on rARFl- 
regulated PLD and found that wortmannin up to 1 PM was 
without effect. In the absence of wortmannin, PEt production 
due to rARF1 and GTP-y-S was 8,240 dpm and it was 8,908 
dpm in the presence of 1 ,uM wortmannin. 
4. Discussion 
Phospholipase D activation by cell-surface receptors is 
a well-documented response observed in many cell-types but 
its function is not yet established [ 11. The mechanism of its regu- 
A. Control +PMA 
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Fig. 3. PMA pretreatment potentiates rARFl-regulated PLD activity. 
Human neutrophils were pretreated with PMA (100 nM) for 5 min 
prior to penneabilization with streptolysin 0 for 10 min. The cells were 
washed and incubated with 10 PM GTP-y-S, 4 nmol rARF1, 1 ,uM 
Ca2+, 1 mM MgATP and 1% ethanol for 30 min to assay for PLD 
activity. 100 nM PMA was added into the assay where indicated. 
Analysis of radioactivity (A) by Bioimager and (B) by scintillation 
counting. 
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Fig. 4 (A) MgATP potentiates ARF-regulated PLD activity. Neutro- 
phils were metabolically inhibited prior to permeabilization to reduce 
intracellular levels of MgATP. Cytosol-depleted neutrophils were as- 
sayed for PLD activity for 30 min in the presence at 1 PM Ca*’ and 1% 
ethanol. rARF1 (4 nmol), GTP-y-S (10 PM) and indicated concentra- 
tions of MgATP were presented where indicated. (B) Neomycin inhibits 
rARFl-regulated PLD activity in the presence or absence of MgATP. 
Legend as in A except that the concentration fneomycin and MgATP 
were both at 1 mM. 
lation has been intensively studied, and evidence for both 
GTP-binding proteins and PKC has been reported [l]. ARF 
has been recently identified as the GTP-binding protein respon- 
sible for regulating PLD in undifferentiated HL60 cells, a pro- 
myelocytic cell-line [ 16,171. In this study we report the require- 
ment for ARF as an activator of PLD in human neutrophils 
and show that the ARFl-dependent PLD activity is greatly 
potentiated by PMA, an activator of PKC and by MgATP. 
Many of the characteristics of rARFl-reconstituted PLD 
activity in the cytosol-depleted human neutrophils examined 
here resemble those observed in HL60’s, a related cell line, 
when endogenous cytosol was present [12,20]. For example, 
synergistic activation of PLD with PMA and GTP-y-S and 
enhancement by MgATP are observed under both situations. 
In studies in HL60’s where GTP-y-S was added during perme- 
abilization, PLD activity was found to be greatly enhanced as 
the concentration of Ca” was increased from nanomolar to 
micromolar [12,20]. It was therefore surprising to note that 
rARFl-reconstituted PLD activity (Fig. 2B) was not dependent 
on Ca” to the same degree. This may reflect cell-specific differ- 
ences. 
PKCs are predominantly cytosolic in neutrophils and their 
activation with PMA involves the increased association of the 
enzymes with membranes [25]. 9 isoforms of PKCs have been 
identified; and classied as conventional PKCs (cFKC) which 
are Ca2’-dependent or novel PKCs (nPKC) which are Ca2’- 
independent [26]. Neutrophils possess both cPKCs and nPKCs 
[27]. In neutrophils the predominant isoform that translocates 
to membranes in response to PMA is the cPKC isoform /3 
[25,27]. Since PMA pretreatment is necessary to observe the 
increase in the rARFl-regulated PLD activity, the most likely 
candidate responsible for this effect is the translocated PKC B. 
The target for the PKC is not known but could conceivably be 
PLD itself. 
The observation that GTP-y-S-regulated PLD activity is en- 
hanced by MgATP has previously been interpreted to be due 
to the activation of PLC and hence PKC [12]. This interpreta- 
tion is no longer tenable for two reasons. In cytosol-depleted 
cells used in this study, [I] an effect of PMA is only observed 
provided that the PKCs are recruited to the membrane prior 
to permeabilization. [2] PLC activation is greatly reduced due 
to loss of a cytosolic protein, phosphatidylinositol transfer pro- 
tein [21]. 
It has recently been reported that ARF can only activate a 
solubilized PLD in the presence of PI(4,5)P, [16]. We have 
previously shown that in the absence of MgATP, the pol- 
yphosphoinositide levels drop significantly and re-addition of 
MgATP at millimolar concentrations restores these levels [28]. 
The enhancement with MgATP when ARF-regulated PLD is 
examined in its natural environment may reflect the increased 
availability of PIP,. The observation that neomycin, which 
binds to polyphosphoinositides selectively [29] inhibited ARFl- 
regulated PLD activity specifically provides direct proof that 
the polyphosphoinositides play a role not only in vitro [ 161 but 
also when the substrate, PC, is presented in its natural environ- 
ment. 
The fungal metabolite wortmannin is a potent inhibitor of PI 
3-kinase in neutrophils [23,24] as well as fMetLeuPhe-mediated 
PLD activation in intact neutrophils [30-321. PMA or A23 187 
stimulation of PLD is unaffected by wortmannin, suggesting 
that direct inhibition of the enzyme is unlikely, and that events 
upstream of PLD activation are the target for wortmannin 
inhibition [33]. Since wortmannin is without effect on rARFl- 
regulated PLD, it follows that it is not PIP, that enhances 
rARFl-reconstituted PLD activity in the presence of MgATP. 
A major goal is to identify by which mechanism receptor 
activation leads to the activation of PLD in neutrophils. We 
would assume that there is an ARF exchange factor that is 
responsible for exchanging GDP for GTP on ARF. A possible 
signal that may be responsible for ARF activation could be 
derived from the PI 3-kinase pathway. The fMetLeuPhe recep- 
tor activates PI 3-kinase through By-subunits and wortmannin 
has been shown to be a direct inhibitor of this activity 
[23,24,34]. fMetLeuPhe-mediated PLD activation in intact neu- 
trophils is also potently inhibited by wortmannin [30-321. Since 
we show that ARFl-regulated PLD activity is not inhibited 
directly by wortmannin, this would support the concept hat the 
PLD pathway is downstream to the PI 3-kinase pathway. 
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